Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Semaglutide Prior to Radical Prostatectomy for Intermediate-risk Localized Prostate Cancer
NCT07727473Phase 1Not yet recruiting
- Sponsor
- Banner Health
- Start
- Jul 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of semaglutide in prostate cancer (PCa), sponsored by Banner Health. Primary endpoints: Change in Caspase-3 (CC3) activation up to 6 months, Change in Ki-67 proliferative index up to 6 months and 2 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07727473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07727473.